The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs)

Biochimie

Volumn 79, Issue 2-3, 1997, Pages 95-99

  Staels, B ^a   Schoonjans, K ^a   Fruchart, J C ^a   Auwerx, J ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Apolipoproteins; Gene expression; Lipoprotein lipase; Nuclear receptors; Triglyceride metabolism

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN C3; CELL NUCLEUS RECEPTOR; FIBRIC ACID DERIVATIVE; LIPOPROTEIN LIPASE; LIVER ENZYME; MESSENGER RNA; PEROXISOME PROLIFERATOR; THIAZOLIDINE DERIVATIVE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL;

ADIPOSE TISSUE; DRUG MECHANISM; ENZYME ACTIVATION; GENE INDUCTION; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIVER METABOLISM; SHORT SURVEY; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030743034     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(97)81497-6     Document Type: Article

References (39)

1. Schoonjans K, Staels B, Auwerx J (1996) Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res 37, 907-925
2. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM (1995) 15-Deoxy-D12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83, 803-812
3. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehman JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83, 813-819
4. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270, 12953-12956
5. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA (1995) Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270, 23975-23983
6. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91, 7355-7359
7. Isseman I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650
8. Beck F, Plummer S, Senior PV, Byrne S, Green S, Brammar WJ (1992) The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat. Proc Royal Soc Lond Biol 247, 83-87
9. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W (1995) Differential expression of peroxisome proliferator-activated receptors: tissue distribution of PPARα, β and γ in the adult rat. Endocrinology 137, 354-366
10. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8, 1224-1234
11. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79, 1147-1156
12. Parra HJ, Arveiller D, Evans AE, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, Douste-Blazy P, Luc G, Richard JL, Ducimetière P, Fruchart JC, Cambien F (1992) A case-control study of lipoprotein particles in two poulations at contrasting risk for coronary heart disease: the ECTIM study. Arterioscler Thromb 12, 701-707
13. Wang CS, McConathy WJ, Kloer HU, Alaupovic P (1985) Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 75, 384-390
14. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV (1986) Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 78, 1287-1295
15. Windler E, Chao Y, Havel RJ (1980) Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. J Biol Chem 255, 8303-8307
16. Quarfordt SH, Michalopoulos G, Schirmer B (1982) The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem 257, 14642-14647
17. Malmendier CL, Lontie JF, Delcroix C, Dubois DY, Magot T, De Roy L (1989) Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis 77, 139-149
18. Rees A, Shoulders CC, Stocks J, Galton DJ, Baralle FE (1983) DNA polymorphism adjacent to human apoprotein A-I gene: relation to hypertriglyceridemia. Lancet i, 444-446
19. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL (1993) An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 90, 4562-4566
20. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL (1990) Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 249, 790-793
21. de Silva HV, Lauer SJ, Wang J, Simonet WS, Weisgraber KH, Mahley RW, Taylor JM (1994) Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 269, 2324-2335
22. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J (1994) Targetted disruption of the apolipoprotein C-III gene in mice results in hypertriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 269, 23610-23616
23. Auwerx J, Leroy P, Schoonjans K (1992) Lipoprotein lipase: Recent contributions from molecular biology. C Rev Clin Sci 29, 243-268
24. Brunzell JD (1989) Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: The metabolic basis of inherited disease, 6th edition (Scriver CR, Beaudet AL, Sly WS, Valle D, eds) McGraw Hill, New York, 1165-1180
25. Babirak SP, Iverius PH, Fujimoto WY, Brunzell JD (1989) Detection and characterization of the heterozygote state for lipoprotein lipase deficiency. Arterioscler Thromb 9, 326-334
26. Miesenbock G, Holzl B, Foger B, Brandstatter E, Paulweber B, Sandhofer F, Patsch JR (1993) Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. J Clin Invest 91, 448-455
27. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T (1990) Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Drug Res 40, 156-162
28. Schonfeld G (1994) The effects of fibrates on lipoprotein and hemostatic risk factors. Atherosclerosis 111, 161-174
29. Staels B, Auwerx J (1992) Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alpha-fetoprotein as models. Development 115, 1035-1043
30. Staels B, Vu-Dac N, Kosykh V, Saladin R, Fruchart JC, Dallongeville J, Auwerx J (1995) Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl Co-enzyme A oxidase. J Clin Invest 95, 705-712
31. Schoonjans K, Peinado-Onsurbe J, Heyman R, Briggs M, Cayet D, Deeb S, Staels B, Auwerx J (1996) PPARα and PPARα activators direct a tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15, 5336-5348
32. Ladias JAA, Hadzopoulou-Cladaras M, Kardassis D, Cardot P, Cheng J, Zannis V, Cladaras C (1992) Transcriptional regulation of human apolipoprotein genes apoB, apoCIII, and apoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3. J Biol Chem 267, 15849-15860
33. Mietus-Snyder M, Sladek FM, Ginsburg GS, Kuo CF, Ladias JAA, Darnell JEJ, Karathanasis SK (1992) Antagonism between apolipoprotein AI regulatory protein 1, Ear3/COUP-TF, and hepatocyte nuclear factor 4 modulates apolipoprotein CIII gene expression in liver and intestinal cells. Mol Cell Biol 12, 1708-1718
34. Hertz R, Bishara-Shieban J, Bar-Tana J (1995) Mode of action of peroxisome proliferators as hypolipidemic drugs, suppression of apolipoprotein C-III. J Biol Chem 270, 13470-13475
35. Heller F, Harvengt C (1983) Effects of clofibrate, bezafibrate, fenofibrate, and probucol on plasma lipolytic enzymes in normolipidaemic subjects. Eur J Clin Pharmacol 23, 57-63
36. Sommariva D, Bonfiglioloi D, Pogliaghi I, Zanaboni L, Balboni E (1983) Effects of procetofen on serum lipids and lipoproteins and on post-heparin lipase activities in type II and in type IV hyperlipoproteinemic patients. Curr Ther Res 34, 907-915
37. Weisweiler P (1989) Low-dose cholestipol plus fenofibrate: effects on plasma lipoproteins, lecithin: cholesterol acyltransferase, and post-heparin lipases in familial hypercholesterolemia. Metabolism 38, 271-275
38. Simpson HS, Williamson CM, Olivecrona T, Pringle S, Maclean J, Lorimer AR, Bonnefous F, Bogaievsky Y, Packard CJ, Shepherd J (1990) Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 85, 193-202
39. Rouffy J, Goy-Loeper J, Chanu B, Bakir R, Djian F (1985) Comparative study of reduction in serum lipids obtained with bezafibrate and fenofibrate in twenty patients with type II hyperlipoproteinemia and low serum HDL. Sem Hôpitaux 61, 2115-2120